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Abstract
Background: Migraine Disability Assessment Scale (MIDAS) is a useful tool to measure headache-related disability.
Modified MIDAS with 4-week recall period reduces recall bias and improves accuracy of the results. This study
aimed at validating mMIDAS in Portuguese.
Methods: Studied population consisted of adult migraine patients attending a headache outpatient clinic.
Reliability was assessed by internal consistency and reproducibility in a 3-week test-retest. Content validity was
evaluated by two expert panels. Construct validity was tested by comparing mMIDAS-P index in socioeconomic
and clinical patient groups and scale unidimensionality was evidenced by factor analysis. Criterion validity was
tested using EQ-5D-5L and HADS.
Results: Ninety-two patients, 88% female, mean age of 44 years, participated. They had, in average, 9.7 headache
days in previous month, pain averaging 7.5/10. About 69.9% were on a migraine prophylactic treatment, and 42.4%
had severe disability; 29.4 and 13.0% showed, respectively, moderate/severe anxiety and depression. Content
validity showed that mMIDAS-P is simple and clinically useful. It did not show to be determined by patient’s
sociodemographic characteristics and it was correlated with depression scale and EQ-5D-5L. Test-retest
demonstrated high reproductive reliability and good internal consistency.
Conclusion: mMIDAS-P is valid and reliable. We strongly recommend it for clinical and research use.
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Background
Migraine is an episodic primary headache syndrome, the
most common type of headache worldwide, affecting 1
out of 10 people [1]. Although pain is the most commonly
reported symptom, migraine is associated with non-
painful symptomatology, including aura, prodrome and
postdrome symptoms, which can be as disabling as pain
itself, with all its spectrum of manifestations. Migraine is a
highly disabling condition, with impact at the social,
family and professional levels, profoundly affecting patient
quality of life (QoL). In Portugal, headache disorders are
the third most disabling health problem with over 2
million people suffering from migraine in the country; its
prevalence is 18.1%, all ages [2].
A useful tool to measure this disability is the Migraine
Disability Assessment Scale (MIDAS), developed after
1998 by Stewart and colleagues [3–6], aimed to improve
the communication between care providers and migraine
patients. It was developed from the Headache Impact
Questionnaire (GImQ) to measure headache severity,
excluding the pain dimension, to obtain an easier way to
compute a global score [7]. MIDAS has been largely used
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to evaluate the impact of migraine and has been proven
simple to use, consistent, highly reliable, and correlating
well with physicians’ clinical judgments in several studies,
not only in USA and UK English [6, 8], but also in many
other languages. Among such languages, we may cite, by
alphabetic order, Arabic [9], Chinese [10], French [11],
German [12], Greek [13], Hindi [14], Italian [15], Japanese
[16], Malay [17], Persian [18], Portuguese-Brazil [19],
Spanish [20], Thay [21], and Turkish [22]. MIDAS also
proved to be useful to identify adequate treatments and to
stratify them based on the level of patient disability [9, 23].
Recently, a minor modification was performed in
the original MIDAS questionnaire: the recall time was
changed from 3-months to 4-weeks [24]. This modifi-
cation was expected to reduce recall bias and improve
accuracy of the results, and termed the questionnaire
mMIDAS.
Portuguese is the ninth most spoken language in the
world, with 234 million speakers and, although MIDAS
had previously been translated into European Portuguese,
it had not yet been validated in this language. The authors
endeavoured to apply this translated version of MIDAS on
a migraine Portuguese population, to evaluate the reliabil-




This study aimed at validating mMIDAS and studying
the QoL of a sample of migraine patients. Under no
circumstances, it interfered with health professionals’
decisions concerning the most appropriate medical ap-
proach for each patient. Before data collection, all partici-
pants filled in a written informed consent and this study
received the approval from the Ethics Commission of the
Coimbra University Hospital.
Participants
The study was conducted between September 25th and
December 6thth 2019 at the Neurology Department of
Coimbra University Hospital. Studied population
consisted of consecutive adult patients observed in a
headache outpatient clinic. These were evaluated and
included in the study by a clinician if older than 18
years, with chronic or episodic migraine, with ability to
give consent to participate in the study, and if able to
read and write Portuguese for self-completion of ques-
tionnaires. Excluded were unstable patients or with
uncontrolled symptoms and considered by clinicians as
unable to fill the measures, cognitively affected, and
those who could not understand Portuguese. The ques-
tionnaire was completed during the consultation.
Measures
Besides mMIDAS, we applied a generic QoL instrument
(EQ-5D-5L), two questions about satisfaction with life
and social support, a specific psychological instrument
to measure anxiety and depression (HADS); and a short
socioeconomic set of questions.
mMIDAS is a self-administered questionnaire that
contains seven questions about the headache a patient
had in the previous month [3–6]. The first five questions
assess the impact of migraine on three domains of daily
activity: two questions for paid work or schoolwork, two
questions for household work, and one question for
family, social and leisure activities. The two questions
for each of the first two groups assess, respectively, the
number of days off due to headache, and the number of
days in which the productivity was reduced by half or
more.
The sixth and seventh additional questions, for the
clinicians’ benefit, count the frequency of headache days
in the previous month, and the average intensity of the
headache attacks, in a 0 (no pain at all) to 10 (pain as
bad as it can be) scale.
mMIDAS index is derived from the sum of the
answers on the first five questions. This score defines
patients in four categories of headache disability: little/
none disability if the score is between 0 and 5; mild
disability if between 6 and 10; moderate disability if
between 11 and 20; and severe disability if greater than
20 [4–6].
The original version of MIDAS is available on the
National Headache Foundation website and is presented
in the Supplementary file 1. A first Portuguese non-
validated translation of mMIDAS has been provided by
the author through Mapi Research Trust (see Supple-
mentary file 2). Therefore, before implementing this
measure, we decided to validate its contents by clinical
reviews with Portuguese neurologists and by cognitive
debriefings with patients. We also tested its reliability, as
well as its construct and criterion validity.
EQ-5D-5L is a short generic QoL preference measure
that allows generating an index representing the value
assigned to an individual’s health status. It was devel-
oped by the EuroQoL Group in 1987 and it is currently
composed of a descriptive system and a visual analogue
scale (VAS). The descriptive system represents health in
five dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each of these dimen-
sions has five associated severity levels and a weighted
scoring procedure to create an EQ-5D-5L index score [25].
VAS has the appearance of a thermometer (vertical
line with about 20 cm), whose scale ranges from 0 (worst
imaginable health status) to 100 (best imaginable health
status), with the individual having directly to mark what
value s/he attributes to her/his current health status.
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In this study, we have used the Portuguese version
approved by the EuroQoL Group [26].
To measure the satisfaction with life we asked the
patient whether s/he agreed with the sentence “I am
happy with my life”, in a 5-point scale from ‘completely
disagree’ to ‘completely agree’. The social support ques-
tion refers to the expected number of individuals the pa-
tient would be able to ask for help in case of need.
The Hospital Anxiety and Depression Scale (HADS) is
composed by 14 items, grouped in two subscales separ-
ately scored and measuring, respectively, anxiety and
depression. Each item is answered in a 4-point Likert
scale from 0 to 3 and it takes approximately 2–5min to
be completed [27]. For each subscale, a score between 0
and 7 is considered normal, between 8 and 10 mild,
between 11 and 14 moderate and between 15 and 21 severe.
In this study, we have used the Portuguese validated
version [28].
The sociodemographic information included gender,
age, marital status, years of education and employment
status.
We also asked physicians to provide clinical informa-
tion about patient’s health status. This included age of
migraine diagnosis, time of follow-up, headache fre-
quency and characteristics, use of prophylactic treatment
and types of drugs used in the past to prevent headache,
as well as acute headache treatment. At last, we also
collected information on patients’ comorbidities.
Statistically, one first decision we had to make was re-
lated to the use of non-parametric statistics, depending
on whether mMIDAS-P index follows a normal distribution.
Therefore, we firstly raised the following hypothesis:
H1: The distribution of mMIDAS-P index is normal
Reliability
Reliability was assessed through intertemporal stability
and internal consistency. To test the intertemporal sta-
bility, we used the intraclass correlation coefficient
(ICC). To avoid recall bias, eligible patients filled
mMIDAS-P in two consecutive moments 3 weeks apart,
the same interval used by the authors in their original
validation study [4, 5], as well as in some other coun-
tries. As defended by Koo, an ICC score lower than 0.50
corresponds to a weak correlation, between 0.50 and
0.75 to a moderate correlation, between 0.75 to 0.90
to a good correlation and a score higher than 0.90
corresponds to an excellent correlation [29]. We also
looked at the correlation factor between each item of
mMIDAS-P and the whole scale.
The internal consistency was measured by the
Cronbach’s alpha coefficient, where recommended
values should be between 0.70 and 0.90 [30]. For this
study, two hypotheses were raised:
H2: mMIDAS-P shows good intertemporal stability.
H3: mMIDAS-P shows good internal consistency.
Validity
We followed the internationally defined methodology to
validate QoL measures. Under this framework, we tested
content, construct and criterion validity [30]. As a trans-
lated Portuguese version already existed, we started by
asking for a clinical revision performed by two neu-
rologists, and a cognitive debriefing with 10 patients
to guarantee the content validity, i.e., the relevance of
the mMIDAS-P items. We formulated the following
hypothesis:
H4: mMIDAS-P is well accepted by clinicians and
patients, not showing ambiguities, redundancies or lack
of contents.
Construct validity, addressing the theoretical concepts
behind the measurement instrument, encompassed the
structural validity and hypothesis testing [30]. Structural
validity was tested by exploratory factor analysis based
on principal components estimates, having previously
applied the sampling adequacy through the measure of
sample adequacy Kaiser-Meyer-Olkin (KMO) and by
Bartlett’s test of sphericity. A KMO smaller than 0.50,
between 0.50 and 0.60 or between 0.60 and 0.70 is con-
sidered, respectively, unacceptable, poor or fair. Scores
between 0.70 and 0.80, between 0.80 and 0.90 or higher
than 0.90 are considered, respectively, average, good or
very good [31]. Bartlett sphericity test should have an
associated significance of < 0.001. For the selection of
the number of factors, we followed the Kaizer criterion
for eigenvalues greater than 1.
For the hypothesis testing, we formulated several
hypotheses with known-groups or subsamples based on
sociodemographic and clinical variables. Should mMIDAS-
P index be normally distributed, Student’s t-test was to be
used for two independent variables and ANOVA for more
than two independent variables. Should mMIDAS-P
index be not normally distributed, the nonparametric
Kolmogorov-Smirnov and Kruskal-Wallis tests were to
be used. The following hypotheses were then defined:
H5: The structure of mMIDAS-P maintains the
unidimensionality.
H6: mMIDAS-P scores are dependent from sociodemo-
graphic variables.
H7: mMIDAS-P scores are dependent from clinical
variables.
Criterion validity was assessed by comparing mMIDAS-
P index with the ones obtained by HADS and EQ-5D-5L,
considered as gold standard references. We also compared
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mMIDAS-P index with the results from the two additional
questions of mMIDAS questionnaire. The statistical rule
used was mainly based on Spearman’s correlation coeffi-
cient, but Pearson’s correlation was also computed to
detect the role of possible outliers. As defined by Cohen,
correlations smaller than 0.30 are considered weak,
between 0.30 and 0.50 are moderate, and higher than 0.50
are considered strong [32].
By comparing mMIDAS-P with HADS and EQ-5D-5L,
we expected to detect similarities and differences be-
tween dimensions, such as depression [33] and migraine
pain [34]. By comparing with the sixth and the seventh
questions, we expected a positive correlation with
headache frequency, measured by the number of days
with headache, and with the headache intensity, mea-
sured by the average intensity of these headaches.
Therefore, we tested the following hypotheses:
H8: mMIDAS-P index correlates positively with the
number of days with headache.
H9: mMIDAS-P index correlates positively with the
average intensity of headache.
H10: mMIDAS-P index correlates with HADS dimensions
anxiety and depression.




The sample was composed by 92 patients. Socioeco-
nomic characteristics and impact on QoL of patients are
presented in Table 1. Table 2 shows some of the clinical
headache characteristics.
Ninety-two patients, 88% female, with a mean age of
44 years participated. A large percentage was married or
lived together (66.3%), were employed (73.9%), and a
fourth had less than 9 years of education. This sample is
representative to all eligible migraine patients seen by
the Neurology Department of Coimbra University
Hospital.
In what concerns the measure of disability due to
migraine, 68.5% of the patients suffered from moderate
to severe disability and the median score was 16.
Migraine frequency in previous month was 9.78 times
(median = 6). In a scale from 0 to 10, the average intensity
of headache was 7.5 (median = 8).
In general, the QoL self-assessed by patients was
reported as 82.0 from EQ-5D-5L index, and 73.4 from
VAS. Patients also showed normal to mild anxiety
(median 8) and normal depression (median 6). More-
over, 10.9% had severe anxiety and 4.3% were severely
depressed.
Concerning the sentence ‘I am happy with my life’,
52.2% agreed and 22.9% disagreed. In the loneliness
question, 63.1% declared having at least three persons to
ask for help, if needed.
Regarding the clinical variables, patients had their
migraine diagnosis when they were about 31 years of
age, had a follow-up of about 3.8 years, and had had in
average 8.9 headaches in previous month. About 70%
were submitted to a prophylactic treatment, the majority
of them with antiepileptic (54.3%) and antidepressant
drugs (52.2%). In crisis, 97.8% of patients followed an
acute treatment, especially using analgesics (91.3%) and
tryptans (47.8%). In general, the large majority of
patients (79.1%) did not report any other comorbidity.
As mentioned before, we firstly tested whether the
variable mMIDAS-P index was normally distributed
(H1). Following the results of the one-sample Kolmogorov-
Smirnov test (test statistic = 0.225; p < 0.001), we decided to
reject the null hypothesis, i.e., we assumed a non-normality
of the mMIDAS-P index.
Reliability
Table 3 reveals the ICC scores obtained from a 3-week
test-retest on 30 patients, without any dropout. It shows
an overall mMIDAS-P index highly reliable (ICC =
0.903), with partial scores between good (0.891) and
excellent (0.997).
Cronbach’s alpha indicator of internal consistency was
0.793, within the recommended set of values. Therefore,
we did not reject hypotheses H2 and H3.
Furthermore, the correlations between mMIDAS-P
index and each of the five components revealed scores
from moderate (mMIDAS5) to good (mMIDAS4).
Validity
To assess semantic and cultural validity of mMIDAS-P
version provided by Mapi, we asked two neurologists to
perform clinical reviews. Very few and minor changes
were proposed and immediately accepted by the re-
search team. On the other hand, two cognitive debrief-
ing meetings were performed with 10 migraine patients
(two men; eight women), who filled mMIDAS-P in 2.9 ±
1.5 min (median = 2.0 min). Patients did not evidence
difficulties in understanding the measure nor did they
find redundancies or ambiguities in the questions. In
addition, the scores were very easy to be computed. We
did not reject H4.
To test construct validity and the factor structure of
mMIDAS-P index, exploratory factor analysis was
applied to the database of 92 responses. This analysis
allowed us to guarantee the unidimensionality defined
by the author, with 55.6% of explained variance and the
factor loadings as presented in Table 4. The KMO test
obtained was 0.733 and the Bartlett sphericity test had
an associated significance (< 0.001), which allowed us to
pursue with the analysis.
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Table 1 Sociodemographic characteristics of the sample (n = 92)
Variable Value N %
Gender Female 81 88.0
Male 11 12.0




Mean ± standard deviation 44.0 ± 11.9
Median 44
Marital status Single 19 20.7
Married or living together 61 66.3
Widowed/divorced/separated 12 13.1
Years of education 0–4 4 4.4
5–9 19 20.6
10–12 30 32.6
> 12 39 42.4
Employment status Employed 68 73.9
Unemployed/student 14 15.2
Other 10 10.9
mMIDAS index Min – max 0–126
Mean ± standard deviation 28.5 ± 29.7
25th percentile 7
50 th percentile 16
75 th percentile 38
Little or no disability (0–5) 15 16.3
Mild disability (6–10) 14 15.2
Moderate disability (11–20) 24 26.1
Severe disability (> 20) 39 42.4
Migraine frequency (mMIDAS-6) Min-max 0–30
Mean ± standard deviation 9.78 ± 8.9
Median 6
How painful were the headaches, 0–10 (mMIDAS-7) Min-max 0–10
Mean ± standard deviation 7.5 ± 1.9
Median 8
Quality of life (EQ-5D-5L - Index) Min-max 5–100
Mean ± standard deviation 82.0 ± 19.7
Quality of life (EQ-5D-5L - VAS) Min-max 30–100
Mean ± standard deviation 73.4 ± 18.2
Anxiety (HADS) Normal (0–7) 40 43.5
Mild (8–10) 25 27.1
Moderate (11–14) 17 18.5
Severe (15–21) 10 10.9
Min-max 0–18
Mean ± standard deviation 8.0 ± 3.9
Median 8
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Even when including all seven mMIDAS questions in
the factor analysis, the unidimensionality could not be
rejected; however, question mMIDAS7 had a very low
communality (0.196) and the total percent of variance
decreased a little bit to 52.6%. We concluded that it is
better to maintain only the five first questions as part of
the total mMIDAS-P score (H5).
Construct validity was tested by comparing mMIDAS-
P index with patients’ sociodemographic characteristics
(H6). As presented in Table 5, mMIDAS-P did not show
to be determined by patient’s sociodemographic gender,
age or education variables.
However, single patients tend to have a lighter impact
of their migraine.
In what concerns the clinical variables age of migraine
diagnosis, time of follow-up, previous prophylactic treat-
ment, and other comorbidities, mMIDAS-P also showed
not to be determined by any level of these variables (H7).
To test criterion validity, we correlated mMIDAS-P
index with the number of days with headache [mMI-
DAS6]. The result of Spearman’s correlation was 0.793
(p < 0.01), evidencing a positive significant correlation
(H8). We also compared mMIDAS-P index with the
average intensity of headaches (mMIDAS7). In our sam-
ple, the correlation between these two variables was
0.300 (p = 0.004), also evidencing a positive significant
correlation (H9) (Table 6).
The EQ-5D-5L dimensions with higher correlation
scores with mMIDAS-P were pain/discomfort (0.422;
p < 0.001) and anxiety/depression (0.422; p < 0.001).
mMIDAS-P also showed to be correlated with HADS
depression scale (0.568; p < 0.001) (H10) and with both
EQ-5D-5L index (− 0.474; p < 0.001) and VAS (− 0.442;
p < 0.001) (H11).
Discussion
mMIDAS index is based on answers about disability as-
sociated to migraine, in previous month. This disability
is measured in terms of missed days of activity and days
with reduced productivity, considering productivity at
work or school, household work and non-work (family,
social, leisure) activity. With this measure, we assume
that a very severe headache may result in missing more
than one of these activities, and so, a single day of head-
ache may correspond to more than one point in the
index [6, 10]. On the other hand, results show that
mMIDAS-P index was skewed distributed towards high
values, as the 25th, 50th and 75th percentiles were,
respectively, 5 (little/mild disability), 16 (moderate
disability) and 38 (severe disability).
Sociodemographic variables in our study were
similar to those in other MIDAS validations: higher
prevalence of females, patients in the 40–49 age
group, employed, with a better QoL, with mild anxiety,
normal depression, and an average of about 10
episodes of headache in previous month, with an aver-
age severity of 7.5 in a 0–10 scale. In what concerns
happiness with life, more than half of the patients
declared being satisfied and, in general, with enough
social support if needed [4, 5].
We found evidence that migraine patients are more
willing to miss household work than family, social or
Table 1 Sociodemographic characteristics of the sample (n = 92) (Continued)
Variable Value N %
Depression (HADS) Normal (0–7) 57 62.0
Mild (8–10) 23 25.0
Moderate (11–14) 8 8.7
Severe (15–21) 4 4.3
Min-max 0–18
Mean ± standard deviation 6.2 ± 4.2
Median 6




Totally agree 10 10.9
Number of people to ask for help None 5 5.4
1–2 persons 29 31.5
3–5 persons 39 42.4
6 or more persons 19 20.7
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leisure activities, being the employment or school work
the one they are less willing to miss. This can probably
be explained by the fact that, because paid or school
work are considered as more stable activities, they are
more easily remembered by patients, as also hypothesized
by Hung and colleagues [10]. Also, the number of days in
which the activities are reduced by half or more were
always higher than the number of full days missed,
which may inform us that some patients still maintain
their work even suffering from pain [10].
Table 2 Clinical characteristics of the sample (n = 92)
Variable Value N %
Age of migraine diagnosis (years) Min-max 2–76
Mean ± standard deviation 31.2 ± 14.7
< 20 27 29.3
21–39 39 42.4
≥ 40 26 28.3
Time on consultation (years) Min-max 0–37
Mean ± standard deviation 3.8 ± 5.6
< 1 36 39.2
1–3 27 29.3
≥ 4 29 31.5
Frequency of headaches in previous month Min-max 0–30
Mean ± standard deviation 8.9 ± 4.5
Prophylactic treatment Now, continued 41 49.4
Now, not previously 17 20.5
Not now, but previously yes 18 21.7
Never 7 8.4
Previous prophylactic treatment Yes 59 71.1
No 24 28.9
Drugs prescribed Antiepileptic 50 54.3
Antidepressant 48 52.2
Beta-Blockers 34 36.9
Botulinum Toxin A 1 12.0
Calcium Blockers 7 7.6
Non-Steroidal anti-Inflammatory 4 1.4
Neuromodulation Devices 1 1.1
Invasive Treatments 1 1.1
Other 10 10.9
Acute treatment for migraine Yes 89 97.8
No 2 2.2







Other comorbidities Yes 18 20.9
No 68 79.1
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The average mMIDAS-P index was 28.5 and the range
varied from 0 to 126. Regarding the question mMIDAS7
addressing the average intensity of headache pain, we
obtained (Table 3) a lower reliability (ICC = 0.780).
However, we did not feel any need to modify the
question as happened in Hindi [14] and in Turkish [22]
versions. Likewise, we decided to maintain mMIDAS6 as
it was, and not use intervals instead of fixed number of
days, as proposed by the French version [11].
Even recognizing that older studies used Pearson’s or
Spearman’s correlations to test intertemporal stability
and newer studies used ICC, the reliability scores
obtained in this study (ICC = 0.821 and alpha = 0.793)
are comparable with the ones reported by other coun-
tries’ studies. Table 7 presents the reliability scores of
validations in other languages.
Also, the correlation factors between each mMIDAS-P
item and the whole scale gave correlations between
0.564 (moderate) and 0.853 (good), all of them signifi-
cant (p < 0.01). Internal consistency Cronbach’s alpha is
very comparable with the values obtained in the original
version and from other languages.
In what concerns validity, mMIDAS-P results are, in
general, comparable with other validation studies, even
with different methodology. UK and USA [5], Japan [16]
and Thailand [21], compared their results with 90-day
diary measures patients were supposed to fill; some
studies did it with HIT-6 as Hindi version [14], and
some others with SF-12, SF-36 or RAND-36, as the
Persian [18] or Greek [13] versions. However, as far as
we know, our version is the first one comparing MIDAS
scores with psychological indicators and preference-
based QoL measures.
The construct validity confirmed the unidimensional-
ity of mMIDAS-P, as in the original version and the
results from Shaik [17] and Mourad [9]. The Spanish
version [20], however, in a population of young university
students, presented a 2-factor structure, one composed by
engagement in activities (items 1, 3 and 5), and the other
corresponding to the performance at work (items 2 and 4).
Comparing mMIDAS-P index with scores obtained in
known-groups, we found no significant differences
among the several levels of patients’ characteristics,
namely gender, age and education, as well as clinical var-
iables age of migraine diagnosis, time of follow-up, pre-
vious prophylactic treatment, and other comorbidities.
Criterion validity was tested by comparing the
mMIDAS-P index with the two extra mMIDAS items,
with self-reported anxiety and depression from HADS
and with QoL scores provided by EQ-5D-5L. Portuguese
mMIDAS index showed a positive and significant correl-
ation with both extra items, with anxiety index, espe-
cially with pain/discomfort and anxiety/depression of
EQ-5D-5L. It should be noted that mMIDAS focusses
on symptoms related with migraine.
One limitation of this study may derive from the sam-
ple size. We collected data from 92 migraine patients,
very close from our initial goal of having 100 patients.
However, considering the COSMIN checklist [35] and
the non-existed missing values, our sample size may be
considered very good for the measurement properties
we used to validate mMIDAS.
A second possible limitation may lie in the patients’
characteristics of our sample. These patients were
recruited from an ambulatory department’s migraine
Table 3 ICC for test-retest study
Because of headaches, during last month, Test (n = 92) Retest (n = 30) Correlation
Mean Median Mean Median ICC with MIDAS-P
[1] # missed days of work or school 2.07 0.0 1.60 0.0 0.9972 0.6971
[2] # days with productivity reduced by half or more 7.90 5.0 8.50 4.5 0.9572 0.8281
[3] # missed days of household work 5.64 2.0 9.03 3.0 0.9812 0.7491
[4] # days with household work productivity reduced by half or more 9.47 5.5 9.60 6.0 0.9502 0.8531
[5] # missed days of family, social or leisure activities 3.54 2.0 2.53 1.0 0.8912 0.5641
MIDAS- P index 28.5 16.0 29.2 20.0 0.9032
[6] # days with headache 9.78 6.0 10.5 10.0 0.8322
[7] In a 0–10 scale, on average, how painful were these headaches 7.49 8.0 8.07 8.0 0.7802
1 p < 0.01 2 p < 0.001
Table 4 Factor analysis scores
Because of headaches, during last month, Factor loadings
[1] # missed days of work or school 0.738
[2] # days with productivity reduced by half or more 0.821
[3] # missed days of household work 0.746
[4] # days with household work productivity reduced
by half or more
0.839
[5] # missed days of family, social or leisure activities 0.548
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consultation of a general hospital. Considering the mMI-
DAS index, circa than one third of them had, at most, a
mild migraine. We are confident that our range is
representative from the actual distribution of migraine
patients from the general population.
A third issue we should address is that, when we com-
pare mMIDAS scores with those obtained from more gen-
eric measures we may run the risk of comparing with a
wider range of symptoms. However, migraine, when ex-
ists, usually dominates all other sources of discomfort, and
so, we think that the comparisons made were appropriate.
Conclusion
This study supports the use of the Portuguese version
of mMIDAS (mMIDAS-P) is a valid and reliable in-
strument to evaluate disability caused by migraine.
Table 5 mMIDAS scores for different levels of sociodemographic and clinical variables
Variable Value n Mean Comparisons mMIDAS Grade Disability
Test Statistic (sig) None/little/mild moderate severe χ2 (sig)
Gendera Female 81 28.7 0.940 86.2% 79.2% 94.9% 3.617 (p = 0.164)
Male 11 25.5 (p = 0.340) 13.8% 20.8% 5.1%
Ageb 19–39 31 20.3 3.202 44.8% 37.5% 23.1% 5.335 (p = 0.255)
40–49 33 33.8 (p = 0.202) 34.5% 25.0% 43.6%
50–78 28 31.1 20.7% 37.5% 33.3%
Marital statusa Single 19 13.7 1.666 31.0% 33.3% 5.1% 9.998 (p = 0.007)
Non-single 73 32.3 (p = 0.008) 69.0% 66.7% 94.9%
Years of educationa ≤ 12 years 53 24.0 1.236 72.4% 54.2% 48.7% 3.982 (0.137)
> 12 years 39 34.9 (p = 0.094) 27.6% 45.8% 51.3%
Age of migraine diagnosis (years)b ≤ 20 27 21.0 1.025 34.5% 25.0% 28.2% 1.095 (p = 0.895)
21–39 39 28.8 (p = 0.599) 37.9% 50.0% 41.0%
≥ 40 26 35.8 27.6% 25.0% 30.8%
Time of follow-up (years) b < 1 36 32.3 0.578 34.5% 37.5% 43.6% 1.914 (p = 0.752)
1–3 27 26.4 (p = 0.749) 31.0% 37.5% 23.1%
≥ 4 29 25.6 34.5% 25.0% 33.3%
Previous prophylactic treatmenta Yes 59 32.0 0.896 64.0% 61.9% 81.1 3.270 (p = 0.195)
No 24 24.2 (p = 0.399) 36.0% 38.1% 18.9
Other comorbiditiesa Yes 18 25.8 0.512 22.2% 17.4% 22.2% 0.238 (p = 0.888)
No 68 29.2 (p = 0.956) 77.8% 82.6% 77.8%
aIndependent-samples Kolmogorov-Smirnov test; bIndependent-samples Kruskal-Wallis test
Table 6 Correlation between mMIDAS scores, QoL variables and headache characteristics
Variable Pearson r Spearman rho
Headaches # days with headache 0.836 (p < 0.001) 0.792 (p < 0.001)
Average intensity 0.346 (p = o.001) 0.300 (p = 0.004)
HADS Anxiety 0.181 (p = 0.084) 0.160 (p = 0.128)
Depression 0.507 (p < 0.001) 0.339 (p = 0.001)
EQ-5D-5L Mobility 0.183 (p = 0.080) 0.104 (p = 0.326)
Self-care 0.306 (p = 0.003) 0.157 (p = 0.136)
Usual activities 0.648 (p < 0.001) 0.512 (p < 0.001)
Pain/discomfort 0.507 (p < 0.001) 0.408 (p < 0.001)
Anxiety/depression 0.537 (p < 0.001) 0.422 (p < 0.001)
Index −0.675 (p < 0.001) −0.474 (p < 0.001)
VAS −0.457 (p < 0.001) −0.442 (p < 0.001)
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Our results are consistent with the original version as
well as with other validation studies.
It is suitable for use in clinical practice as a decision
aid tool to improve health care strategies centered on
migraine patients. It allows the assessment of the impact
on disability and improves the relationship and the com-
munication between physician and patient [36]. It has
also shown to be well accepted by migraine patients.
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